Thermo Fisher Scientific Inc. $TMO Stock Position Lifted by Sarasin & Partners LLP

Sarasin & Partners LLP boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 266,872 shares of the medical research company’s stock after buying an additional 17,018 shares during the quarter. Thermo Fisher Scientific makes up about 1.6% of Sarasin & Partners LLP’s holdings, making the stock its 22nd biggest position. Sarasin & Partners LLP owned approximately 0.07% of Thermo Fisher Scientific worth $133,799,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of TMO. Legacy Wealth Managment LLC ID increased its position in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares during the last quarter. High Note Wealth LLC lifted its holdings in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares during the last quarter. JPL Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at approximately $28,000. Swiss RE Ltd. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Finally, Birchwood Financial Partners Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the topic of several analyst reports. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price target for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Barclays increased their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $579.85 on Friday. The firm has a market capitalization of $214.40 billion, a PE ratio of 31.19, a PEG ratio of 2.35 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm’s fifty day simple moving average is $515.61 and its 200 day simple moving average is $510.03.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.